Allworth Financial LP Cuts Position in Humana Inc. (NYSE:HUM)

Allworth Financial LP decreased its position in shares of Humana Inc. (NYSE:HUM) by 26.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 364 shares of the insurance provider’s stock after selling 130 shares during the period. Allworth Financial LP’s holdings in Humana were worth $92,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV grew its holdings in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Humana in the third quarter worth about $31,000. Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. Atwood & Palmer Inc. boosted its holdings in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares during the period. Finally, LRI Investments LLC grew its position in Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after acquiring an additional 143 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

HUM has been the subject of a number of analyst reports. Barclays increased their price objective on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. JPMorgan Chase & Co. reduced their price target on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and upped their target price for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus target price of $285.68.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.32% of the company’s stock.

Humana Trading Down 0.3 %

NYSE:HUM opened at $255.02 on Tuesday. The stock has a market cap of $30.77 billion, a price-to-earnings ratio of 25.63, a PEG ratio of 2.05 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company’s 50 day moving average price is $269.30 and its 200-day moving average price is $288.93. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.39%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s payout ratio is presently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.